ONTRUZANT® (trastuzumab-dttb) for Injection, for Intravenous Use 21 mg/mL

What conditions is ONTRUZANT used to treat (indications)?

Adjuvant Breast Cancer. ONTRUZANT is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one ...
Support and coverage

Remember, you are not alone.
Patient support for ONTRUZANT is available.

Patient Support for ONTRUZANT® (trastuzumab-dttb) Is Available Not an actual patient.

The Organon Access Program for ONTRUZANT

The Organon Access Program (OAP) may be able to answer your questions about insurance coverage, co-pay assistance for eligible patients, eligibility determination, and more. You can:

Speak to A Representative By Calling 844-326-2986

Speak to a
representative
by calling
844-326-2986

Learn About Options for Co-Pay Assistance for Eligible Patients

Learn about
options for co-pay
assistance for
eligible patients

Find Out About Insurance Coverage for ONTRUZANT® (trastuzumab-dttb) Costs, Including Any Out-of-Pocket Costs

Find out about insurance
coverage for ONTRUZANT
costs, including any
out-of-pocket costs

Visit The Organon Access Program
Download patient brochure

IMPORTANT SAFETY INFORMATION

ONTRUZANT treatment can result in heart problems. Serious and sometimes fatal events have occurred. Some patients have had serious and fatal infusion reactions and lung problems. Symptoms usually occur during or within 24 hours of administration. ONTRUZANT can cause harm to an unborn baby, in some cases death of the unborn baby, when taken by a pregnant woman. ONTRUZANT treatment may lead to a worsening of low white blood cell count.

ORGANON
Accessibility Icon TRUSTe APEC Privacy

© 2021 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies. US-SBF-115118 08/21

This site is intended only for residents of the United States, its territories, and Puerto Rico.